MedTrace Logo

Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression

NCT05749289 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2026-04-06

No results posted yet for this study

Summary

This is an open-label whole-body PET/CT study for investigating the value of Al18F-octreotide PET/CT in patients with SSTR positive tumors

Conditions

  • SSTR Positive Tumors

Interventions

DRUG

Al18F-octreotide

Al18F-octreotide I was injected into the patients before the PET/CT scans

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Rong Zheng, M.D. · National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and PUMC

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-20
Primary Completion
2028-12-20
Completion
2029-12-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05749289 on ClinicalTrials.gov